NASDAQ:SGEN - Seattle Genetics Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Seattle Genetics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $113.98 -0.15 (-0.13 %) (As of 12/10/2019 04:00 PM ET) Add Compare Today's Range$113.05Now: $113.98▼$114.6750-Day Range$98.86MA: $112.08▼$121.8152-Week Range$51.50Now: $113.98▼$122.36Volume1.39 million shsAverage Volume947,252 shsMarket Capitalization$19.53 billionP/E RatioN/ADividend YieldN/ABeta2.03 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Seattle Genetics, Inc, a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company markets ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas. It also conducts various clinical trials to evaluate the combination of ADCETRIS and nivolumab to treat patients with relapsed or refractory, or transplant-ineligible, advanced classical Hodgkin lymphoma; relapsed or refractory B-cell and T-cell non-Hodgkin lymphomas; second-line Hodgkin lymphoma; and relapsed/refractory classical Hodgkin lymphoma, as well as to treat Hodgkin lymphoma in patients with age 60 years or older. Read More… Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:SGEN Previous Symbol CUSIP81257810 CIK1060736 Webhttp://www.seattlegenetics.com/ Phone425-527-4000Debt Debt-to-Equity RatioN/A Current Ratio4.86 Quick Ratio4.49Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$654.70 million Price / Sales29.84 Cash FlowN/A Price / Cash FlowN/A Book Value$7.95 per share Price / Book14.34Profitability EPS (Most Recent Fiscal Year)($1.65) Net Income$-222,690,000.00 Net Margins-37.97% Return on Equity-19.17% Return on Assets-15.99%Miscellaneous Employees1,302 Outstanding Shares171,386,000Market Cap$19.53 billion Next Earnings Date2/6/2020 (Estimated) OptionableOptionable Receive SGEN News and Ratings via Email Sign-up to receive the latest news and ratings for SGEN and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:SGEN Rates by TradingView Seattle Genetics (NASDAQ:SGEN) Frequently Asked Questions What is Seattle Genetics' stock symbol? Seattle Genetics trades on the NASDAQ under the ticker symbol "SGEN." How were Seattle Genetics' earnings last quarter? Seattle Genetics, Inc. (NASDAQ:SGEN) announced its earnings results on Tuesday, October, 29th. The biotechnology company reported ($0.55) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.36) by $0.19. The biotechnology company had revenue of $213.26 million for the quarter, compared to analyst estimates of $211.85 million. Seattle Genetics had a negative return on equity of 19.17% and a negative net margin of 37.97%. The firm's revenue for the quarter was up 25.9% on a year-over-year basis. During the same period last year, the firm earned ($0.42) earnings per share. View Seattle Genetics' Earnings History. When is Seattle Genetics' next earnings date? Seattle Genetics is scheduled to release their next quarterly earnings announcement on Thursday, February 6th 2020. View Earnings Estimates for Seattle Genetics. What price target have analysts set for SGEN? 19 brokerages have issued 1 year price targets for Seattle Genetics' shares. Their forecasts range from $74.00 to $140.00. On average, they expect Seattle Genetics' share price to reach $109.93 in the next year. This suggests that the stock has a possible downside of 3.6%. View Analyst Price Targets for Seattle Genetics. What is the consensus analysts' recommendation for Seattle Genetics? 19 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Seattle Genetics in the last year. There are currently 6 hold ratings and 13 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Seattle Genetics. What are Wall Street analysts saying about Seattle Genetics stock? Here are some recent quotes from research analysts about Seattle Genetics stock: 1. According to Zacks Investment Research, "Seattle Genetics reported narrower-than-expected loss in Q1 while revenues beat estimates.Its sole marketed drug, Adcetris, is performing well since its launch. Adcetris’ recent label expansion in frontline stage III/IV Hodgkin lymphoma and in frontline CD30-expressing peripheral T-cell lymphomas (PTCL) bodes well for the company. The company’s collaboration with Takeda for the global development and commercialization of Adcetris also holds promise. However, its heavy dependence solely on Adcetris for growth is a concern. The recent label expansion of Merck’s Keytruda and Bristol-Myers’ Opdivo in the lymphoma indication will increase competition. Though the company has multiple candidates in its pipeline, maximum is in early developmental stages. Any regulatory setback for Adcetris could hurt its sales potential significantly." (5/29/2019) 2. JPMorgan Chase & Co. analysts commented, "Quarter as We maintain our Neutral rating on ZBH shares following 1Q19 results that came in-line with Street expectations (but missed our more bullish forecast) on the top-line with slightly higher expenses than we forecasted. While Hips (+1.7% xFx) and Dental (-0.2% xFx) were bright spots relative to expectations, Knees (+0.7% xFx) continues to remain challenged relative to market growth particularly within the Americas (-0.9% xFx). Importantly volume gains overall were +220bps Y/Y and only negative 30bps Q/Q from a seasonally strong 4Q18. While pricing pressures have not abated, we think the volume gains are notable for ZBH considering the overall pricing environment seen across all large cap orthopedics thus far this season." (4/28/2019) 3. HC Wainwright analysts commented, "We reach a price target of $98 after adjusting new corporate tax rate, cash, and other program updates. The price target is based on a sum-of-parts NPV-DCF ($63.1 HL + $3.6 relapsed sALCL+ $11.2 frontline PTCL + $17.6 platform + $2.6 cash). Key risks to achievement of our target price include trial failures, safety issues, regulatory delays, competition, and dilutive financing. Seattle Genetics Inc. April 26, 2019 H.C. WAINWRIGHT & CO. EQUITY RESEARCH 2Seattle Genetics, Inc." (4/26/2019) Has Seattle Genetics been receiving favorable news coverage? Media coverage about SGEN stock has trended neutral this week, InfoTrie Sentiment Analysis reports. InfoTrie identifies positive and negative news coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Seattle Genetics earned a coverage optimism score of 0.4 on InfoTrie's scale. They also gave media stories about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an effect on the company's share price in the near future. View News Stories for Seattle Genetics. Who are some of Seattle Genetics' key competitors? Some companies that are related to Seattle Genetics include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Regeneron Pharmaceuticals (REGN), Alexion Pharmaceuticals (ALXN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS), Exelixis (EXEL) and Repligen (RGEN). What other stocks do shareholders of Seattle Genetics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Seattle Genetics investors own include Immunomedics (IMMU), Celgene (CELG), Gilead Sciences (GILD), Incyte (INCY), Netflix (NFLX), Alibaba Group (BABA), Alexion Pharmaceuticals (ALXN), NVIDIA (NVDA), Micron Technology (MU) and AbbVie (ABBV). Who are Seattle Genetics' key executives? Seattle Genetics' management team includes the folowing people: Dr. Clay B. Siegall, Co-Founder, Chairman, Pres & CEO (Age 58)Mr. Todd E. Simpson, Chief Financial Officer (Age 58)Dr. Vaughn B. Himes, Chief Technology Officer (Age 58)Dr. Roger D. Dansey M.D., Chief Medical Officer (Age 62)Ms. Jean I. Liu, Gen. Counsel, Exec. VP of Legal Affairs & Corp. Sec. (Age 51) Who are Seattle Genetics' major shareholders? Seattle Genetics' stock is owned by many different of retail and institutional investors. Top institutional shareholders include State Street Corp (1.92%), First Trust Advisors LP (0.54%), Point72 Asset Management L.P. (0.43%), Pictet Asset Management Ltd. (0.39%), Manning & Napier Group LLC (0.35%) and Sumitomo Mitsui Trust Holdings Inc. (0.28%). Company insiders that own Seattle Genetics stock include Bros Advisors Lp Baker, Clay B Siegall, Darren S Cline, David W Gryska, Jean I Liu, Jonathan G Drachman, Lip Bu Tan, Marc E Lippman, Roger D Dansey, Srinivas Akkaraju, Todd E Simpson and Vaughn B Himes. View Institutional Ownership Trends for Seattle Genetics. Which institutional investors are selling Seattle Genetics stock? SGEN stock was sold by a variety of institutional investors in the last quarter, including First Trust Advisors LP, Manning & Napier Group LLC, Russell Investments Group Ltd., Fjarde AP Fonden Fourth Swedish National Pension Fund, Squarepoint Ops LLC, Sumitomo Mitsui Trust Holdings Inc., Stifel Financial Corp and Lagoda Investment Management L.P.. Company insiders that have sold Seattle Genetics company stock in the last year include Clay B Siegall, David W Gryska, Jean I Liu, Lip Bu Tan, Marc E Lippman, Roger D Dansey, Srinivas Akkaraju, Todd E Simpson and Vaughn B Himes. View Insider Buying and Selling for Seattle Genetics. Which institutional investors are buying Seattle Genetics stock? SGEN stock was purchased by a variety of institutional investors in the last quarter, including State Street Corp, Pictet Asset Management Ltd., State of New Jersey Common Pension Fund D, Point72 Asset Management L.P., California Public Employees Retirement System, Castleark Management LLC, CIBC Asset Management Inc and Maverick Capital Ltd.. View Insider Buying and Selling for Seattle Genetics. How do I buy shares of Seattle Genetics? Shares of SGEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab. What is Seattle Genetics' stock price today? One share of SGEN stock can currently be purchased for approximately $113.98. How big of a company is Seattle Genetics? Seattle Genetics has a market capitalization of $19.53 billion and generates $654.70 million in revenue each year. The biotechnology company earns $-222,690,000.00 in net income (profit) each year or ($1.65) on an earnings per share basis. Seattle Genetics employs 1,302 workers across the globe.View Additional Information About Seattle Genetics. What is Seattle Genetics' official website? The official website for Seattle Genetics is http://www.seattlegenetics.com/. How can I contact Seattle Genetics? Seattle Genetics' mailing address is 21823 30TH DRIVE SE SUITE, BOTHELL WA, 98021. The biotechnology company can be reached via phone at 425-527-4000 or via email at [email protected] MarketBeat Community Rating for Seattle Genetics (NASDAQ SGEN)Community Ranking: 2.5 out of 5 ( )Outperform Votes: 604 (Vote Outperform)Underperform Votes: 610 (Vote Underperform)Total Votes: 1,214MarketBeat's community ratings are surveys of what our community members think about Seattle Genetics and other stocks. Vote "Outperform" if you believe SGEN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SGEN will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 12/10/2019 by MarketBeat.com StaffFeatured Article: Depreciation
